Novoron’s scientific foundation is the discovery of a novel receptor for the components of myelin that inhibit regeneration of the central nervous system (CNS) after injury (1). This pioneering research has led to a novel approach to nerve regeneration that is applicable to a number of CNS disorders and diseases, including spinal cord injury, multiple sclerosis and glaucoma. Novoron’s proprietary technology has been exclusively licensed from the University of California, San Diego (2).
Myelin forms a protective covering around nerves, allowing them to rapidly transmit signals to efficiently facilitate vision and coordinate body movement. Disease and injury can cause demyelination. The body has a natural mechanism for remyelination, but during injury or disease the process can be overwhelmed by myelin debris.
In neurons, LRP1 (low density lipoprotein-related protein-1) contributes to myelin-mediated inhibition of axonal regeneration via activation of Rho. Impairing LRP1 function via genetic silencing or antagonism via RAP (receptor associated protein) blocks activation of Rho and restores neuronal outgrowth.
Novoron is pursuing novel biologic therapeutics to inhibit the LRP1/Rho pathway and, thus, promote neuronal and axonal regeneration.
(1) LDL receptor-related protein-1 is a sialic-acid-independent receptor for myelin-associated glycoprotein that functions in neurite outgrowth inhibition by MAG and CNS myelin. Travis L. Stiles, Travis L. Dickendesher, Alban Gaultier, Anthony Fernandez-Castaneda, Elisabetta Mantuano, Roman J. Giger, Steven L. Gonias. Journal of Cell Science (2013) 126: 209-220; doi: 10.1242/jcs.113191
(2) U.S. Provisional Patent 61/479,210; PCT application filed in April 2012